ASTM E 2799 : 2022
Current
The latest, up-to-date edition.
Standard Test Method for Testing Disinfectant Efficacy against Pseudomonas aeruginosa Biofilm using the MBEC Assay
Hardcopy , PDF
English
30-05-2022
Committee |
E 35
|
DocumentType |
Test Method
|
Pages |
9
|
PublisherName |
American Society for Testing and Materials
|
Status |
Current
|
Supersedes |
1.1This test method specifies the operational parameters required to grow and treat a Pseudomonas aeruginosa biofilm in a high throughput screening assay known as the MBEC (trademarked)2 (Minimum Biofilm Eradication Concentration) Physiology and Genetics Assay. The assay device consists of a plastic lid with ninety-six (96) pegs and a corresponding receiver plate with ninety-six (96) individual wells that have a maximum 200 μL working volume. Biofilm is established on the pegs under batch conditions (that is, no flow of nutrients into or out of an individual well) with gentle mixing. The established biofilm is transferred to a new receiver plate for disinfectant efficacy testing.3, 4 The reactor design allows for the simultaneous testing of multiple disinfectants or one disinfectant with multiple concentrations, and replicate samples, making the assay an efficient screening tool.
1.2This test method defines the specific operational parameters necessary for growing a Pseudomonas aeruginosa biofilm, although the device is versatile and has been used for growing, evaluating and/or studying biofilms of different species as seen in Refs (1-4).5
1.3Validation of disinfectant neutralization is included as part of the assay.
1.4This test method describes how to sample the biofilm and quantify viable cells. Biofilm population density is recorded as log10 colony forming units per surface area. Efficacy is reported as the log10 reduction of viable cells.
1.5Basic microbiology training is required to perform this assay.
1.6The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.
1.7ASTM International takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.
1.8This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
1.9This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
ASTM E 2756 : 2024 | Standard Terminology Relating to Antimicrobial and Antiviral Agents |
ASTM E 1054 : 2022 | Standard Practices for Evaluation of Inactivators of Antimicrobial Agents |
ASTM E 1054 : 2021 : EDT 1 | Standard Practices for Evaluation of Inactivators of Antimicrobial Agents |
ASTM E 2756 : 2024 : REV A : EDT 1 | Standard Terminology Relating to Antimicrobial and Antiviral Agents |
ASTM E 2756 : 2024 : REV A | Standard Terminology Relating to Antimicrobial and Antiviral Agents |
ASTM E 2756 : 2019 | Standard Terminology Relating to Antimicrobial and Antiviral Agents |
Access your standards online with a subscription
Features
-
Simple online access to standards, technical information and regulations.
-
Critical updates of standards and customisable alerts and notifications.
-
Multi-user online standards collection: secure, flexible and cost effective.